Sofinnova Investments, Inc.
About Sofinnova Investments, Inc.’s 13F portfolio
Sofinnova Investments, Inc. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Sofinnova Investments, Inc. reported $1.9B across 53 US-listed positions (). Its largest position is Natera Inc (NTRA) at 22% of the reported book, and its ten biggest holdings make up 60% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: NTRA Natera Inc | — — | 22% | 1.6M | $420.8M |
| 2 | NASDAQ: VERA Vera Therapeutics Inc | — — | 6.4% | 2.8M | $119.9M |
| 3 | NASDAQ: GMAB Genmab A/S | — — | 5.9% | 4.0M | $111.1M |
| 4 | NASDAQ: JAZZ Jazz Pharmaceuticals PLC | — — | 4.7% | 365K | $88.0M |
| 5 | NASDAQ: RAPP Rapport Therapeutics Inc | — — | 4.2% | 1.9M | $79.4M |
| 6 | NASDAQ: SPTX Seaport Therapeutics Inc | — — | 4.1% | 3.6M | $77.4M |
| 7 | NASDAQ: AVBP Arrivent BioPharma Inc | — — | 3.1% | 1.7M | $58.9M |
| 8 | NASDAQ: RARE Ultragenyx Pharmaceutical In | — — | 3.1% | 1.7M | $57.3M |
| 9 | NASDAQ: BIOA BioAge Labs Inc | — — | 3.0% | 2.3M | $56.2M |
| 10 | NYSE: BMY Bristol-Myers Squibb Co | — — | 2.7% | 877K | $50.5M |
| 11 | NASDAQ: SUPN Supernus Pharmaceuticals | — — | 2.6% | 1.0M | $48.2M |
| 12 | NASDAQ: RYTM Rhythm Pharmaceuticals Inc | — — | 2.4% | 408K | $45.3M |
| 13 | NASDAQ: GILD Gilead Sciences Inc | — — | 2.3% | 343K | $43.3M |
| 14 | NASDAQ: UTHR United Therapeutics Corp Del | — — | 2.2% | 76K | $41.4M |
| 15 | NASDAQ: COGT Cogent Biosciences Inc | — — | 2.1% | 1.0M | $40.1M |
| 16 | NASDAQ: AXSM Axsome Therapeutics Inc. | — — | 2.1% | 160K | $39.3M |
| 17 | NASDAQ: IMTX Immatics N.V | — — | 2.0% | 3.7M | $37.2M |
| 18 | NASDAQ: DYN Dyne Therapeutics Inc | — — | 2.0% | 1.7M | $36.8M |
| 19 | NASDAQ: IMNM Immunome Inc | — — | 1.9% | 1.7M | $36.5M |
| 20 | NASDAQ: IDYA IDEAYA Biosciences Inc | — — | 1.8% | 925K | $34.5M |
| 21 | NASDAQ: ANAB Anaptysbio Inc | — — | 1.8% | 494K | $33.3M |
| 22 | NASDAQ: NKTR Nektar Therapeutics | — — | 1.8% | 472K | $32.9M |
| 23 | NASDAQ: PHVS Pharvaris N V | — — | 1.6% | 881K | $30.5M |
| 24 | NYSE: RCUS Arcus Biosciences Inc | — — | 1.6% | 946K | $29.2M |
| 25 | NASDAQ: INBX Inhibrx Biosciences Inc | — — | 1.5% | 303K | $28.7M |
Showing 1–25 of 53 positions on this page reported in this 13F.
- Healthcare94%
- AddedGMABGenmab A/S+438%$111.1M
- NewSPTXSeaport Therapeutics Inc—$77.4M
- AddedSUPNSupernus Pharmaceuticals+8.6%$48.2M
- NewGILDGilead Sciences Inc—$43.3M
- AddedIMTXImmatics N.V+1.1%$37.2M
- AddedDYNDyne Therapeutics Inc+1.5%$36.8M
- AddedIMNMImmunome Inc+1.1%$36.5M
- AddedANABAnaptysbio Inc+98.8%$33.3M
- AddedPHVSPharvaris N V+7.7%$30.5M
- AddedRCUSArcus Biosciences Inc+2.4%$29.2M
- ReducedJAZZJazz Pharmaceuticals PLC−38.9%$88.0M
- ReducedRAREUltragenyx Pharmaceutical In−45.4%$57.3M
- ReducedBMYBristol-Myers Squibb Co−55.9%$50.5M
- ReducedRYTMRhythm Pharmaceuticals Inc−9.3%$45.3M
- ReducedUTHRUnited Therapeutics Corp Del−52.2%$41.4M
- ReducedCOGTCogent Biosciences Inc−51.0%$40.1M
- ReducedAXSMAxsome Therapeutics Inc.−24.6%$39.3M
- ReducedIDYAIDEAYA Biosciences Inc−18.3%$34.5M
- ReducedNKTRNektar Therapeutics−7.4%$32.9M
- ReducedINBXInhibrx Biosciences Inc−25.3%$28.7M
Reading Sofinnova Investments, Inc.’s 13F portfolio
Sofinnova Investments, Inc.’s $1.9B 13F book is spread across 53 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 60%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are NTRA, VERA, GMAB, JAZZ and RAPP, led by Natera Inc (NTRA) at 22% of the portfolio. The heaviest sector exposure is Healthcare (94%).
What Sofinnova Investments, Inc. changed last quarter
Between 2026-03-31 and Q2 2026, Sofinnova Investments, Inc. was a net seller: it opened 11 new positions and added to 12 more, while trimming 17 and closing 19 outright. Against a 53-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Genmab A/S (GMAB), and its biggest reduction was Jazz Pharmaceuticals PLC (JAZZ).
What a 13F does and doesn’t reveal
A 13F captures only Sofinnova Investments, Inc.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Sofinnova Investments, Inc. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Sofinnova Investments, Inc.'s profile on this page is built directly from those filings.
How current is the 13F data on Sofinnova Investments, Inc.'s page?
It reflects Sofinnova Investments, Inc.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Sofinnova Investments, Inc. files its next quarterly report, this page refreshes automatically.
Can I see Sofinnova Investments, Inc.'s complete list of holdings?
This page highlights Sofinnova Investments, Inc.'s largest positions rather than all 53 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Sofinnova Investments, Inc.'s filings.
Does a 13F show everything Sofinnova Investments, Inc. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Sofinnova Investments, Inc.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Sofinnova Investments, Inc. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

